trial

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

NCTId NCT04118127
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 73 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2021-02-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
73 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-10-17
Primary completion
2021-02-16
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
2mg conventional tablet, once-weekly tablets

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Takehisa MatsumaruStudy Director

Sites

1 total
Tokyo, Japan

Facts & assertions

4 sourced
Enrollment
73
Phase
PHASE1
Primary Completion Date
2021-02-16
Status
COMPLETED
relationships
The graph out of here
drug
2mg conventional tablet, once-weekly tablets
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Takehisa Matsumaru
person